23
Participants
Start Date
January 1, 2018
Primary Completion Date
May 15, 2019
Study Completion Date
May 15, 2019
Escitalopram + RT2CK17
Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
Escitalopram + Placebo
Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
Laureate Institute for Brain Research, Tulsa
Lead Sponsor
Laureate Institute for Brain Research, Inc.
OTHER